ESGN

Ensysce Biosciences is a clinical-stage biotech company focused on developing safer prescription drugs to combat opioid abuse and overdose. The company utilizes its proprietary Trypsin-Activated Adenyl-Prodrug (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms to create tamper-proof medications. Its lead candidate, PF614, is a TAAP-protected oxycodone prodrug designed to reduce non-oral abuse and prevent accidental overdose. By requiring activation by intestinal trypsin, these therapies aim to provide effective pain relief while significantly lowering the risk of misuse. The company's technology is designed to prevent common methods of drug abuse such as crushing, snorting, or injecting. Ensysce is currently advancing its pipeline through clinical trials with the goal of providing clinicians with safer alternatives for pain management.